Home>>Signaling Pathways>> Others>>FPR Agonist 43

FPR Agonist 43 (Synonyms: FPR Agonist 43)

Catalog No.GC36075

An agonist of FPR1 and FPR2

Products are for research use only. Not for human use. We do not sell to patients.

FPR Agonist 43 Chemical Structure

Cas No.: 903895-98-7

Size Price Stock Qty
10mM (in 1mL DMSO)
$188.00
In stock
5mg
$171.00
In stock
10mg
$261.00
In stock
25mg
$513.00
In stock
50mg
$819.00
In stock
100mg
$1,305.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

FPR Agonist 43 (compound 43) is a dual formyl peptide receptor 1 (FPR1) and formyl peptide receptor 2 (FPR2)/ALX agonist[1][2]. FPR1, FPR2/ALX[1]

FPR Agonist 43 (10-5-107 nM) is actively potent in the cAMP assay in FPR2/ALX over-expressing CHO cells[1]. FPR Agonist 43 is also active in the GTPγ binding assay (IC50=207±51 nM)[1].FPR1 is the preferred receptor for FPR Agonist 43 in in both human neutrophils and possibly also in mouse cells[2]. Cell Viability Assay[1] Cell Line: Chinese hamster ovary (CHO) over-expressing human FPR2/ALX receptors

[1]. PlanagumÀ A, et al. Lack of activity of 15-epi-lipoxin A? on FPR2/ALX and CysLT1 receptors in interleukin-8-driven human neutrophil function. Clin Exp Immunol. 2013 Aug;173(2):298-309. [2]. Forsman H, et al. What formyl peptide receptors, if any, are triggered by compound 43 and lipoxin A4• Scand J Immunol. 2011 Sep;74(3):227-234.

Reviews

Review for FPR Agonist 43

Average Rating: 5 ★★★★★ (Based on Reviews and 34 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for FPR Agonist 43

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.